Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7703043rdf:typepubmed:Citationlld:pubmed
pubmed-article:7703043lifeskim:mentionsumls-concept:C0231335lld:lifeskim
pubmed-article:7703043lifeskim:mentionsumls-concept:C0027708lld:lifeskim
pubmed-article:7703043lifeskim:mentionsumls-concept:C0232164lld:lifeskim
pubmed-article:7703043lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:7703043lifeskim:mentionsumls-concept:C0001758lld:lifeskim
pubmed-article:7703043lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:7703043pubmed:issue1lld:pubmed
pubmed-article:7703043pubmed:dateCreated1995-5-10lld:pubmed
pubmed-article:7703043pubmed:abstractTextTo assess the cardiotoxicity of moderate doses of anthracyclines and to control for possible contributions of other drugs, cardiac function in 12 patients 1 year 11 months to 9 years 4 months off treatment for Wilms' tumor whose therapy had included vincristine, dactinomycin, and the anthracycline doxorubicin (270 to 300 mg/m2 cumulative dose) was compared with that of 9 patients (controls) whose therapy had included vincristine and dactinomycin but not doxorubicin. The small numbers of patients studied suggest that a a medium of 6 years off therapy only small numbers of patients will have cardiac function values below age-related normal values. To confirm these results and to determine whether abnormalities are progressive or are clinically important, large cohorts of patients such as those available to the National Wilms' Tumor Study need to be studied.lld:pubmed
pubmed-article:7703043pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7703043pubmed:languageenglld:pubmed
pubmed-article:7703043pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7703043pubmed:citationSubsetIMlld:pubmed
pubmed-article:7703043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7703043pubmed:statusMEDLINElld:pubmed
pubmed-article:7703043pubmed:issn0888-0018lld:pubmed
pubmed-article:7703043pubmed:authorpubmed-author:BlattJJlld:pubmed
pubmed-article:7703043pubmed:authorpubmed-author:FrickerF JFJlld:pubmed
pubmed-article:7703043pubmed:authorpubmed-author:JanoskyJ EJElld:pubmed
pubmed-article:7703043pubmed:authorpubmed-author:DeLaatCClld:pubmed
pubmed-article:7703043pubmed:issnTypePrintlld:pubmed
pubmed-article:7703043pubmed:volume12lld:pubmed
pubmed-article:7703043pubmed:ownerNLMlld:pubmed
pubmed-article:7703043pubmed:authorsCompleteYlld:pubmed
pubmed-article:7703043pubmed:pagination61-6lld:pubmed
pubmed-article:7703043pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:meshHeadingpubmed-meshheading:7703043-...lld:pubmed
pubmed-article:7703043pubmed:articleTitlePilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.lld:pubmed
pubmed-article:7703043pubmed:affiliationDivision of Hematology-Oncology, Children's Hospital of Pittsburgh, Pennsylvania.lld:pubmed
pubmed-article:7703043pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7703043pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed